Compare VVX & VCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VVX | VCEL |
|---|---|---|
| Founded | 2014 | 1989 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Diversified Commercial Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 2.4B |
| IPO Year | 2014 | 1996 |
| Metric | VVX | VCEL |
|---|---|---|
| Price | $79.47 | $42.08 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 8 | 5 |
| Target Price | ★ $69.88 | $57.75 |
| AVG Volume (30 Days) | ★ 673.0K | 444.7K |
| Earning Date | 05-04-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 126.85 | 60.00 |
| EPS | ★ 1.41 | N/A |
| Revenue | ★ $4,480,038,000.00 | $276,259,000.00 |
| Revenue This Year | $7.81 | $19.40 |
| Revenue Next Year | $5.84 | $18.24 |
| P/E Ratio | $58.52 | ★ N/A |
| Revenue Growth | 3.65 | ★ 16.45 |
| 52 Week Low | $50.89 | $28.95 |
| 52 Week High | $93.98 | $49.32 |
| Indicator | VVX | VCEL |
|---|---|---|
| Relative Strength Index (RSI) | 45.80 | 37.01 |
| Support Level | $65.02 | $32.44 |
| Resistance Level | $92.89 | $49.04 |
| Average True Range (ATR) | 4.00 | 1.57 |
| MACD | -0.49 | -0.42 |
| Stochastic Oscillator | 20.62 | 6.80 |
V2X Inc is a U.S.-based company that provides services to the U.S. government. It operates as one segment and offers facility and logistics services and information technology mission support and engineering and digital integration services. The information technology and network communications capabilities consist of communications systems operations and maintenance, management and service support, systems installation and activation, system-of-systems engineering and software development, and mission support for the department of defense. The facility and logistics service include airfield management, ammunition management, civil engineering, communications, emergency services, life support activities, public works, security, transportation operations, and others.
Vericel Corp is a fully integrated commercial-stage biopharmaceutical company and a provider of therapies for the sports medicine and severe burn care markets. It markets cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane); Epicel (cultured epidermal autografts); and NexoBrid. The Company operates its business in the U.S. in one reportable segment; the research, product development, manufacture, and distribution of cellular therapies and specialty biologics for use in the treatment of specific conditions.